Naveen Pemmaraju: Congratulations to Kuo-Kai Chin for being awarded the Ruben Mesa Junior Clinical Investigator Award

Naveen Pemmaraju posted on X/Twitter:

”Congratulations to Kuo-Kai Chin for being awarded the Ruben Mesa Junior Clinical Investigator Award at the 2nd NYC Myeloid Malignancies Workshop for his Project: Menin Inhibitor Revumenib in patients with Leukemia Associated with HOX Genes.”

Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.